CARMEL, Ind. – Syra Health Corp. (NASDAQ: SYRA), a healthcare technology company with a market capitalization of $8.5 million and showing strong recent momentum with a 19% gain last week, was awarded a contract to Washington DC government up to $1 million to provide health care workforce solutions to the Office of the State Superintendent of Education. Additionally, the company announced an increase in its contract with the Indiana Family and Social Services Administration’s NeuroDiagnostic Institute by $1.2 million, which now totals $18.7 million. According to InvestingPro data, the company maintains a healthy balance sheet with more cash than debt, although analysts note the rapid use of cash.

The new contract in Washington DC involves Syra Health deploying registered nurses, licensed practical nurses, and certified nursing assistants to deliver health care services to students, ensuring their safety and well-being. The company will work within DC regulations and develop individual service plans, with a one-year agreement that allows for potential extensions.

In Indiana, the expanded contract with Syra Health supports the NeuroDiagnostic Institute’s efforts to evaluate and treat patients with complex neuropsychiatric disorders. Dr Deepika Vuppalanchi, CEO of Syra Health, expressed the company’s commitment to drive better health outcomes through these partnerships, noting that this is the fourth government contract in Washington, DC and a continuing their collaboration with the NeuroDiagnostic Institute since 2021.

Syra Health specializes in behavioral and mental health, population health, and healthcare workforce solutions, leveraging advanced technology to improve prevention, access, and efficiency of care. in health.

The press release also contains forward-looking statements about the company’s future plans and prospects, cautioning that these statements are subject to risks and uncertainties. Investors are reminded to consider the risk factors detailed in the company’s annual and periodic SEC filings. The information presented is based on a press release statement from Syra Health.

In other recent news, Syra Health Corp is navigating a potential delisting from the Nasdaq Stock Market for not complying with minimum bid price requirements. The company is given a grace period until April 16, 2025, to ensure that the closing bid price of the common stock reaches or exceeds $1.00 for at least ten consecutive business days. In addition, Syra Health faces a potential delisting due to an equity deficiency and has a 45-day window to present a compliance plan to Nasdaq.

Despite these challenges, Syra Health continues to expand its footprint in the healthcare sector, securing contracts in Florida, Kansas, and Delaware, thus marking its presence in 23 states. The company was also awarded a $5.8 million contract with the Indiana Family and Social Services Administration and won a contract with the Wyoming Department of Health.

In terms of financial developments, Syra Health has raised approximately $2.1 million in a public offering, with potential additional gross income of $4.1 million from the exercise of Series Warrants, according to Rodman & Renshaw LLC. Additionally, the company updated its financial outlook for 2024, projecting revenues between $7.5 million and $9.5 million. These recent developments underscore Syra Health’s continued efforts to navigate financial challenges while continuing to grow its business operations.

This article was created with the support of AI and reviewed by an editor. For more information see our T&C.